Promising ALS drug shows potential in Late-Stage trial
NCT ID NCT04745299
First seen May 03, 2026 · Last updated May 03, 2026
Summary
This phase 3 trial tested a drug called Lenzumestrocel (Neuronata-R) in 123 people with ALS, a progressive nerve disease. The goal was to see if repeated doses could slow the disease and improve survival compared to a placebo. The study measured how well patients functioned and how long they lived over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hanyang university hospital
Seoul, Seoul, 04763, South Korea
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
Pusan National University Yangsan Hospital
Yangsan, Kyungsangnam-do, 50612, South Korea
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.